The effect of GABApentin on neurogenic detrusor overactivity, a pilot study

Carbone, A.; Tubaro, Andrea; Morello, P; Parascani, R.; Catalani, Claudio; Palleschi, Giovanni

doi:10.1016/s1569-9056(03)80559-6

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This further led to the use of gabapentin for the treatment of OAB and nocturia. Carbone et al [9] reported significant modification of urodynamic indexes, particularly for DO, while the symptomatic score evaluation and voiding diary data demonstrated a considerable lowering of the irritative symptoms. Furthermore, they did not record significant adverse effects and no patient stopped the drug treatment.…”

Section: Discussionmentioning

confidence: 97%

Gabapentin: A novel drug as add-on therapy in cases of refractory overactive bladder in children

Ansari

Bharti

Kumar

et al. 2013

Journal of Pediatric Urology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Gabapentin: A novel drug as add-on therapy in cases of refractory overactive bladder in children

Ansari

Bharti

Kumar

et al. 2013

Journal of Pediatric Urology

View full text Add to dashboard Cite

show abstract

“…In a pilot study, Carbone et al (2003) reported on the effect of gabapentin on neurogenic detrusor activity. They found a positive effect on symptoms and a significant improvement of urodynamic parameters after treatment and suggested that the effects of the drug should be explored in further controlled studies in both neurogenic and non-neurogenic detrusor overactivity.…”

Section: Pharmacology Of the Lower Urinary Tractmentioning

confidence: 99%

Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence

Andersson

Wein²

2004

Pharmacol Rev

452

364

View full text Add to dashboard Cite

“…Carbone et al . [97] reported an improvement with gabapentin in urodynamic variables in patients with DO. A major concern with any centrally acting drugs has understandably been their potential for producing side‐effects.…”

Section: Cnsmentioning

confidence: 99%

Developments in pharmacological therapy for the overactive bladder

Chapple

Gormley

2006

BJU International

View full text Add to dashboard Cite

urinary urgency has a significant association with other symptoms of OAB [5,6]. As urgency is the 'driving' symptom in OAB [7], those with OAB often experience urgency at inconvenient and unpredictable times, and consequently often lose control before reaching the toilet. This adversely affects their physical and psychological state by limiting daily activities, intimacy, compromising sexual function, and worsening self-esteem. It is no surprise therefore that patients often consider that improvements in urgency are the most noticeable response to therapy.Many areas of controversy surround the use of the term 'urgency' . Starting with terminology, how does urgency differ from 'urge' or 'the normal desire to void' (the latter in our view being a preferable term). It is a sensory symptom, and as such is difficult to define, to communicate to both patients and colleagues alike, and to measure and quantify, despite the additional variable introduced by inter-individual variation. Furthermore, when OAB has neurological causes, is the sensation different from that in people with idiopathic detrusor overactivity (IDO)?Where is the sensation located; in the suprapubic area or the perineum? Are there differences in the symptom of urgency and its clinical features in men compared to women? Certainly this would be expected to be the case, with a greater likelihood of an association with urgency incontinence and a shorter 'warning' or postponement time in women than men. Therefore it is no surprise that all attempts to quantify this symptom, in particular using warning time, have proved controversial and been of limited success. Clearly, despite the difficulties in its quantification, urgency and the other symptoms of OAB result in a significant deterioration in health-related quality of life (HRQoL) [8,9].To date, patient diaries have been a reliable way to collect OAB symptom data, including urgency episodes, nocturia, micturition and urgency incontinence episodes, and diary entry remains the most accurate and sensitive method for evaluating changes in urgency with pharmacotherapy. Data obtained on the basis of 3-or 4-day diaries suggest that short-duration diaries are just as reliable as those recorded for 7 days and, because they are less of a burden for patients, might be a more acceptable way to assess OAB symptoms [10].The concept of warning-time was introduced with the drug darifenacin, which was initially reported to increase warning-time by a median of 4.3 min compared with placebo [11]. However, the results in that pilot study are far from conclusive, and subsequent studies have failed to show a significant effect on warning-time [12]. WHICH CHOLINERGIC RECEPTOR?The detrusor smooth muscle is rich in cholinergic-muscarinic receptors. Electrical stimulation of an intact cholinergic nerve or application of a cholinergic agonist to a strip of detrusor muscle results in detrusor muscle contraction. All of the drugs approved to date for OAB work on the basis of blocking cholinergic receptors that stabilize the bladder ...

show abstract

The effect of GABApentin on neurogenic detrusor overactivity, a pilot study

Cited by 9 publications

References 0 publications

Gabapentin: A novel drug as add-on therapy in cases of refractory overactive bladder in children

Gabapentin: A novel drug as add-on therapy in cases of refractory overactive bladder in children

Pharmacology of the Lower Urinary Tract: Basis for Current and Future Treatments of Urinary Incontinence

Developments in pharmacological therapy for the overactive bladder

Contact Info

Product

Resources

About